Oral · GLP-1 agonist
RGT001-075 / RGT-075
3 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
3
Active
0
Recruiting
0
Completed
2
Sites
37
Countries
1
Endpoints
58
Composite endpoints
4
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 2
3
Trials by status
Completed
2
Terminated
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
31
Weight & body composition
12
Cardiometabolic biomarkers
9
Glycemic / diabetes
4
MASH / liver
1
Renal / kidney
1
Most-measured metrics
Top 20 metrics across this asset's endpoints
Fasting glucose, changeGlycemic
2
Body weight, absolute change (kg)Weight
2
Treatment-emergent AEs (any)Safety/PK
2
Body weight, % changeWeight
2
AUC₀–∞Safety/PK
2
HbA1c, changeGlycemic
1
BMI, changeWeight
1
Waist circumference, changeWeight
1
HbA1c <7.0% achievementGlycemic
1
≥10% weight-loss respondersWeight
1
Systolic BP, changeBiomarker
1
Diastolic BP, changeBiomarker
1
Heart rate, changeBiomarker
1
ALT, changeMASH
1
eGFR, changeRenal
1
Total cholesterol, changeBiomarker
1
Triglycerides, changeBiomarker
1
HDL-C, changeBiomarker
1
LDL-C, changeBiomarker
1
Thyroid eventSafety/PK
1
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
3 of 3
| Asset / Population | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| COMO-1Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions | RGT001-075 / RGT-075 Obesity / overweight | BMI ≥30 | Ph 2 | Completed | 35 | Nov 2025 | — | |
| NCT06277934A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related Comorbidities | RGT001-075 / RGT-075 Obesity / overweight | BMI ≥27 | Ph 2 | Completed | 10 | Aug 2024 | — | |
| NCT05297045A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes | RGT001-075 / RGT-075 Type 2 diabetes | BMI 24.5-40 | Ph 2 | Terminated | 1 | May 2023 | — |